跳转至内容
Merck
CN
  • Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways.

Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways.

Journal of Cancer (2017-01-11)
Sami Benzina, Jason Harquail, Roxann Guerrette, Pierre O'Brien, Stéphanie Jean, Nicolas Crapoulet, Gilles A Robichaud
摘要

The study of genetic factors regulating breast cancer malignancy is a top priority to mitigate the morbidity and mortality associated with this disease. One of these factors, Pax-5, modulates cancer aggressiveness through the regulation of various components of the epithelial to mesenchymal transitioning (EMT) process. We have previously reported that Pax-5 expression profiles in cancer tissues inversely correlate with those of the Focal Adhesion Kinase (FAK), a potent activator of breast cancer malignancy. In this study, we set out to elucidate the molecular and regulatory relationship between Pax-5 and FAK in breast cancer processes. Interestingly, we found that Pax-5 mediated suppression of breast cancer cell migration is dependent of FAK activity. Our mechanistic examination revealed that Pax-5 inhibits FAK expression and activation. We also demonstrate that Pax-5 is a potent modulator of FAK repressors (p53 and miR-135b) and activator (NFκB) which results in the overall suppression of FAK-mediated signaling cascades. Altogether, our findings bring more insight to the molecular triggers regulating phenotypic transitioning process and signaling cascades leading to breast cancer progression.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
抗 FAK 抗体,克隆 4.47, clone 4.47, Upstate®, from mouse
Sigma-Aldrich
Anti-phospho-Src (Tyr418) 抗体, Upstate®, from rabbit